赛默飞世尔

Thermo Fisher Exec VP Lagarde Sells, Buys Shares Amid Market Volatility

Thermo Fisher

GENinCode Partners with Thermo Fisher to Commercialize Heart Disease Test

Thermo Fisher Scientific Exec Lowery Buys, Sells Shares Amid Market Volatility

Thermo Fisher Scientific Enhances Bioprocessing Capabilities Across Asia with Expanded Bioprocess Design Centers in Hyderabad, Korea, and Singapore

Morgan Stanley Reiterates Overweight on Thermo Fisher, Raises PT to $670

Catalyst<ul> <li>Recent Bullish Engulfing and Strong Bullish evaluations on December 1 and November 25 indicate growing positive momentum for TMO.</li> <li>Analysts have rated TMO as Buy or Strong Buy, showing institutional optimism despite some valuation concerns.</li></ul>Risk<ul> <li>Fund flows show negative trends overall with outflows from small and large orders, which could signal reduced institutional confidence.</li> <li>Technical indicators remain mixed with both Golden Cross and Death Cross signals in the same period, suggesting uncertain market sentiment.</li></ul>

Key Factors

Thermo Fisher Scientific executed a €2.1 billion debt issuance, including €1 billion floating rate notes due 2027 and €1.1 billion fixed rate notes due 2035.Thermo Fisher Scientific Inc. expanded bioprocessing capabilities in Asia with new or expanded Bioprocess Design Centers in Hyderabad, Korea, and Singapore.Thermo Fisher's Executive Vice President Michel Lagarde sold and bought shares in December 2025, including 68,000 shares acquired at $105.17 per share.GENinCode partnered with Thermo Fisher Scientific to commercialize a heart disease test combining molecular diagnostics and predictive algorithms.Morgan Stanley reiterated an Overweight rating on Thermo Fisher Scientific and raised its price target to $670.

TMO News